

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/522,827	01/31/2005	Simona Jevsevar	LB/G-32992A/LEK	2050
1095 NOVARTIS	7590 02/06/200	7	EXAMINER	
CORPORATE INTELLECTUAL PROPERTY ONE HEALTH PLAZA 104/3 EAST HANOVER, NJ 07936-1080			XIE, XIAOZHEN	
			ART UNIT	PAPER NUMBER
			1646	
SHORTENED STATUTOR	Y PERIOD OF RESPONSE	MAIL DATE	DELIVER	Y MODE
31 D	AYS	02/06/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary		Application No.	Applicant(s)				
		10/522,827	JEVSEVAR ET AL.				
		Examiner	Art Unit				
		Xiaozhen Xie	1646				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
WHIC - Extens after S - If NO - Failure Any re	PRTENED STATUTORY PERIOD FOR REPLY HEVER IS LONGER, FROM THE MAILING DASISTANCE OF THE MAILING D	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tirr vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE!	N. sely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status							
1)⊠	1) Responsive to communication(s) filed on <u>31 January 2005</u> .						
,	This action is FINAL . 2b)⊠ This action is non-final.						
•	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition	on of Claims						
5)	Claim(s) <u>1-24</u> is/are pending in the application. 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) <u>1-24</u> are subject to restriction and/or expressions.	vn from consideration.					
Application	on Papers						
10) 🔲 🗆	The specification is objected to by the Examine The drawing(s) filed on is/are: a) accomplicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Ex	epted or b) objected to by the l drawing(s) be held in abeyance. Section is required if the drawing(s) is obj	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).				
Priority u	nder 35 U.S.C. § 119						
a)[Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureausee the attached detailed Office action for a list	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	ion No ed in this National Stage				
2) Notice 3) Inform	t(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate				

Application/Control Number: 10/522,827

Art Unit: 1646

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

- Group I. Claims 1-23 are drawn to a DNA sequence, an expression vector, an expression system, a process for construction of the DNA sequence, and a process for the expression of the DNA sequence.
- Group II. Claim 24 is drawn to a process for the manufacture of a pharmaceutical composition containing hG-CSF.

The inventions listed as I-II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The inventions listed as Groups I-II do not relate to a single general inventive concept because they lack the same or corresponding technical feature. The special technical feature of claim 1, Group I, is a DNA sequence coding for hG-CSF characterized in that the sequence comprises the nucleotide sequence of SEQ ID NO:

1, which is not shared with the Invention claimed in Group II. For example, Groups II is drawn to a method for the manufacture of a pharmaceutical composition containing hG-

Art Unit: 1646

CSF with multiple sequences lack structural similarity. The PCT rules provide for the examination of the 1st claimed product, the 1st claimed method of making that product, and the 1st claimed method of using that product in one application. However, the PCT rules do not provide for the examination of multiple products, multiple methods of making one product, or multiple methods of using one product in one application.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Xiaozhen Xie, Ph.D. whose telephone number is 571-272-5569. The examiner can normally be reached on M-F, 8:30-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary B. Nickol, Ph.D. can be reached 571-272-0835. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/522,827 Page 4

Art Unit: 1646

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Xiaozhen Xie, Ph.D. January 31, 2007

GARY B. NICKOL, PH.D.
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600